Additive interaction of pregabalin with phenytoin in the mouse maximal electroshock-induced seizure model: An isobolographic analysis

Annales Universitatis Mariae Curie-Sklodowska, Sectio DDD: Pharmacia

Volumn 22, Issue 4, 2009, Pages 31-38

  Łuszczki, Jarogniew J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856501521     PISSN: 08670609     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ben-Menachem E.: Pregabalin pharmacology and its relevance to clinical practice. Epilepsia, 45 Suppl. 6, 13, 2004.
2. Borowicz K. K., Świa̧der M., Łuszczki J. et al.: Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia, 43, 956, 2002.
3. Brodie M. J.: Pregabalin as adjunctive therapy for partial seizures. Epilepsia, 45 Suppl. 6, 19, 2004.
4. Dalby N. O., Nielsen E. B.: Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res., 28, 63, 1997.
5. French J. A., Kugler A. R., Robbins J. L. et al.: Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology, 60, 1631, 2003.
6. Kozińska J., Sawicka K. M., Zadrożniak A. et al.: Spironolactone potentiates the protective action of some selected antiepileptic drugs against maximal electroshock-induced seizures in mice. Annales UMCS, Sectio DDD, 22, 123, 2009.
7. Litchfield J. T., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther, 96, 99, 1949.
8. Löscher W., Fassbender C. P, Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res., 8, 79, 1991.
9. Łuszczki J. J., Czuczwar S. J.: Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn-Schmiedebergs Arch. Pharmacol., 374, 51, 2006.
10. Łuszczki J. J.: Interaction of oxcarbazepine with phenobarbital in the mouse pentylenetetrazoleinduced seizure model: an isobolographic analysis. Annales UMCS, Sectio DDD, 22, 61, 2009.
11. Łuszczki J. J.: Isobolographic analysis of interaction between drugs with nonparallel doseresponse relationship curves: a practical application. Naunyn-Schmiedebergs Arch. Pharmacol., 375, 105, 2007.
12. Łuszczki J. J., Antkiewicz-Michaluk L., Czuczwar S. J.: Isobolographic analysis of interactions between 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol., 602, 298, 2009.
13. Macdonald R. L., Greenfield L. J.: Mechanisms of action of new antiepileptic drugs. Curr. Opin. Neurol., 10, 121, 1997.
14. Tallarida R. J.: An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther., 319, 1, 2006.
15. Taylor C. P., Angelotti T., Fauman E.: Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res., 73, 137, 2007.
16. Vartanian M. G., Radulovic L. L., Kinsora J. J. et al.: Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res., 68, 189, 2006.
17. Warner G., Figgitt D. P.: Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs, 19, 265, discussion 273, 2005.